Therefore, the possible effects of the pharmacological blockade of IL-1β receptor in different animal models of colitis should be investigated, in order to find out the better strategy to inhibit the NLRP3 inflammasome pathway and counteract bowel inflammation. Here, NLRP3 is linked to inflammation.